What is next after the genes for autoimmunity?

Castiblanco et al.
What is next after the genes for autoimmunity?

John Castiblanco1,2,3,4, Mauricio Arcos-Burgos5 and Juan-Manuel Anaya1*

Abstract
Clinical pathologies draw us to envisage disease as either an independent entity or a diverse set of traits governed by common physiopathological mechanisms, prompted by environmental assaults throughout life. Autoimmune diseases are not an exception, given they represent a diverse collection of diseases in terms of their demographic profile and primary clinical manifestations. Although they are pleiotropic outcomes of non-specific disease genes underlying similar immunogenetic mechanisms, research generally focuses on a single disease. Drastic technologic advances are leading research to organize clinical genomic multidisciplinary approaches to decipher the nature of human biological systems. Once the currently costly omic-based technologies become universally accessible, the way will be paved for a cleaner picture to risk quantification, prevention, prognosis and diagnosis, allowing us to clearly define better phenotypes always ensuring the integrity of the individuals studied. However, making accurate predictions for most autoimmune diseases is an ambitious challenge, since the understanding of these pathologies is far from complete. Herein, some pitfalls and challenges of the genetics of autoimmune diseases are reviewed, and an approximation to the future of research in this field is presented.

Keywords: Autoimmunity, Common, Genetics, Genomics, Personalized, Predictive medicine, Polyautoimmunity, Translational medicine

Introduction
The everlasting vision of a predictive and preventive framework for disease assessment has pushed the medical sciences to search for new means to manage health care and translate basic research into clinical practice. However, as we dig deeper into the cell and disease mechanisms, the path is not always clear because each new achievement and tool leads to more intricate definitions and targets [1]. Likewise, the cost and configuration of health care plans do not take into consideration the move towards personalized medicine, due in part to the lack of interaction between basic and clinical research. Advances in technology are now prompting this interaction, preparing for more realistic bench to bedside implementation [1-3].

The lack of pathognomonic diagnostic tools and clear-cut diagnostic criteria for complex conditions exposes patients to a bureaucratic limbo, stuck in the system in search of an accurate and complete diagnosis to receive appropriate treatment. Clinical pathologies lead us to consider disease as either an independent entity or a diverse set of traits governed by common physiopathological mechanisms that are prompted by environmental assaults throughout life [4,5]. Autoimmune diseases (ADs) are not an exception. Though the damage to tissues and organs arising from the loss of tolerance is the common attractor to ADs, they represent a diverse collection of diseases defined by their demographic and epidemiological profile, genetic configuration of susceptibility, environmental spectrum and clinical manifestations [4]. Although research more often focuses on a single disease (phenotype), autoimmune phenotypes could represent heterogeneous outcomes of genes underlying similar immunogenic mechanisms, by either cross-phenotype association or by pleiotropy [4,6]. In this sense, clinical observations indicate the possible shift from one disease to another, or the fact that more than one AD may coexist in a single patient (that is, polyautoimmunity) or in the same family (that is, familial autoimmunity) [7].

This article provides a glimpse of the current and future directions for autoimmunity and ADs, discussing the many variables affecting the potential use and application of genetic, evolutionary, demographic, environmental and immunopathological information that could
be used for prediction, prevention and eventually treatment of ADs.

The genetic component of ADs
As multifactorial conditions, ADs develop from the cumulative effect of diverse events on the immune system. It is now clear they do not begin at the time of clinical appearance but rather many years before (Figure 1). This window of clinical silence offers the possibility of predicting ADs [8].

Familial aggregation is observed in ADs, but the prevalence in close relatives of affected individuals is usually lower than would be expected if these conditions were Mendelian-like [9]. Recurrent associations have been reported in the literature [10-12]. The diseases of this aggregated pattern share similar genetic risk factors, including the major histocompatibility complex and also non-major histocompatibility complex variants [13-15] (Figure 2). A higher concordance rate of ADs in monozygotic than in dizygotic twins supports a significant effect of genes additively contributing to autoimmunity [16]. Although there is higher concordance in monozygotic twins, environment, stochastic phenomena and exposure still result in discordance in disease thresholds among such twin pairs [17]. Reported heritability, based on available twin concordance rates and prevalence estimated for ADs as a group, ranges from 0.008 for systemic sclerosis to 1.0 for Crohn's disease, with a median value close to 0.6 [18]. ADs are not inherited in a classical Mendelian pattern, but instead have a complex, yet incompletely defined mode of inheritance [19-21]. Further study is needed on environmental and epigenetic factors to clarify their role and effect to allow a greater understanding of their influence, along with genetics, in defining the onset and progression of ADs. The National Institute of Environmental Health Sciences through expert panel workshops has started revisions of such factors to support this growing field of autoimmunity research [22]. For instance, exposure to organic solvents has been shown to affect the risk to develop ADs [23].

Age remains an important topic in autoimmunity, not only because of the biological implications of aging on the immune system but also because of the setback it constitutes for epidemiologic studies [27]. Further complications arise when two diseases are so far apart at their time of diagnosis that a rigorous follow-up becomes imperative to find co-occurrence in one patient [28].

The reason for a major prevalence of ADs among women is poorly understood. The more frequent the AD and the later it appears, the more women are affected [29]. The most convincing explanation of female-biased autoimmunity remains the hormonal theory. Hormones such as estrogens and prolactin have been studied for increasing susceptibility to ADs and can affect both innate and adaptive immune systems [29]. Generally, women have a stronger humoral and cellular immune response than men.

In complex traits, allelic architecture challenges the identification of common and rare genomic variants and their potential effect on risk or protection to develop ADs [15]. Several strategies have been considered to
dissect variants either associated or co-segregating with ADs (that is, association or linkage approaches such as family-based co-segregation analysis) [9,15]. For association studies, two approaches are available: genome-wide association studies (GWAS) and candidate gene studies. The genome-wide association approach is usually hypothesis-free whereas the candidate gene is hypothesis-driven.

A leap forward towards the recognition of more genes coincided with the advent of high-throughput genotyping technologies and genetic variation repositories, which allowed the use of large sample cohorts to screen for new variants. GWAS interrogate the vast majority of known common polymorphisms [30,31]. This strategy led to a broad array of studies of different AD cohorts (Figure 3), aiming to disclose either new genes or loci associated with ADs or to replicate previously reported associations (Figure 2). Guidelines for the design, quality control and interpretation of GWAS have been presented elsewhere [32-34], as well as novel approaches to study shared genetic factors (for example, cross-phenotype meta-analysis) [35,36].

The overarching conclusion after the first round of GWAS reports is that genetic heterogeneity, epistasis and complex interactions, plus demographic and environmental factors, underpin the susceptibility to ADs [13-15]. It is unclear how many genetic variants are associated with ADs, and what the immunomolecular mechanisms underlying epistasis among them are. However, a full inventory of variants is not far away and new approaches to examine epistasis will tell us how genes interact to confer either susceptibility or protection against ADs [37]. On top of this genetic view, newly published and publicly available data (for example, exome sequencing project, HapMap and the 1000 genomes project) are at par with technological approaches probing other omic layers like gene expression (for example, RNA-seq, Ribo-seq), methylation (for example, Methyl-seq; BS-seq, Bisulfite Sequencing), other epigenetic marks (for example, ChiP-seq, Chromatin Immunoprecipitation sequencing; FAIRE-seq, formaldehyde-assisted isolation of regulatory elements–sequencing) and genome structure (for example, Immuno-seq, PhIT-Seq, phenotypic interrogation via tag sequencing) [38] are gaining further attention and application to be compared and matched between their omic counterparts. Current ongoing approaches mapping genetic variation contributing to transcriptional variation, referred to as expression quantitative trait locus analyses [39,40], are assessing the role of genetic variants on the expression of genes in their vicinity; empirically, these approaches have been demonstrated to be well-powered to detect regulatory

Figure 2 Weighted list created from the reported significant mapped genes in the current genome-wide association studies curated from the National Human Genome Research Institute and the database of genotypes and phenotypes. The word cloud shows the frequency of genes and its associated variants relative to their font size using a freely available java applet [24]. Both databases (accessed April 2013) [25,26] were queried taking into account P-values reported for the genetic variants associated with autoimmune disease. For the National Human Genome Research Institute, a total of 12,064 genetic variants were encountered, out of which 1,370 were variants significantly associated with autoimmune disease susceptibility. In the database of genotypes and phenotypes, out of 31,246 reported variants, 972 were mutually exclusive from the National Human Genome Research Institute, for a grand total of 2,342 genetic variants related to genes associated in a genome-wide association study of any population. The autoimmune diseases of interest were autoimmune thyroid disease, Behçet’s disease, celiac disease, rheumatoid arthritis, inflammatory bowel disease, juvenile rheumatoid arthritis, Kawasaki disease, multiple sclerosis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, systemic sclerosis, systemic lupus erythematosus, type 1 diabetes and vitiligo.
effects [41,42]. This type of post-omic information will add to current knowledge and provide new insights for mechanism and molecular processes for specific phenotyped cells and traits related to the autoimmunity phenomena.

**Pitfalls and challenges of complex trait analysis**

In recent years, a plethora of new susceptibility genetic variants for ADs has emerged. The advent and advance of microarray and next-generation sequencing technologies has resulted in commercially available tools to provide and obtain genotypes and sequencing information in a fast but costly manner. This exponential production of data is reflected in the number of manuscripts reporting associations of hundreds of loci to ADs. Thus far, the human leukocyte antigen locus has disclosed the strongest association with ADs [43]. In the case of systemic lupus erythematosus, a simple search in PubMed reported more than 5,000 papers on the genetics of the disease. These describe more than 40 loci, replicated by several independent studies, that modify the risk to acquire the disease. However, these systemic lupus erythematosus-associated loci explain a minimal portion of the additive heritability, challenging the idea that this new genetic knowledge might allow for a better predictive and preventive assessment of ADs (that is, missing heritability). Table 1 summarizes the main pitfalls and challenges of complex trait analyses, which we will comment upon next.

Two major challenges in studying ADs are the genetic heterogeneity, referring to how a set of genetic variants might define a trait onset either by their combination or differential effect, and pleiotropy [6], where a single gene leads to multiple phenotypic expressions or disorders. As mentioned by Lehner [44], the sharp statement by Sewal Wright in the 1930s that ‘each character is affected by many characters…’ is very much true today.

Diverse human populations present different allelic and genotype structures depending upon their evolutionary and epidemiological history [45]. In addition, the effects of genotype on phenotype for any given population may depend on the environment and length of exposure to an undefined etiological insult. Differences in allele and genotype frequencies among populations reflect the contribution of evolutionary forces such as selection, genetic drift, mutation and migration [46], which might explain why some risk alleles to autoimmunity may be protective factors to infectious diseases and vice versa [47]. Immune and infectious agents have been recognized as among the strongest selective pressures for natural populations [47]. Further research regarding exploration of the interplay between infection, type of exposure, additional environmental factors (for example, microbiota) and autoimmunity will result in the discovery of multiple factors underpinning perhaps newly identified physiopathology mechanisms of ADs.

The relatively short evolutionary time since the rise of modern humans after the clash of cultures in America (500 years) is a perfect scenario to dissect specific immunity associated with infectious diseases and its role in predisposition to ADs. Classical examples are Chagas’
Pharmacogenomics Disentangle markers capable of predicting and diagnosing risk of disease even before onset of disease (originally found in America and absent in other continents) and typhoid fever (brought to America by the Spaniards conquers). Indeed, it is not only the knowledge that might be contributed by this type of population, but also the specific and direct epidemiological and health care approach that must be provided to them. Admixed populations such as Afro-American and Latin-American are often medically underserved and bear a disproportionately high burden of disease. Thus, given the diversity of their genomes, these populations have both advantages and disadvantages for genetic studies of complex phenotypes [48]. Advances in statistical methodologies that use genetic contributions from ancestral populations contributing to the current admixed population have proven to be a powerful method to leverage the confounder effect of ancestry, and this information is used to identify chromosomal segments linked to disease [46]. Consequently, there is a need to explore genetic associations in diverse populations. Proper matching of cases and controls is a major consideration for GWAS, as well as in any case–control association study. The use of ancestry informative markers either to match or exclude cases and controls given specific patterns of genetic stratification allows us to overcome this limitation, diminishing the possibility of reaching spurious associations as a consequence of case–control ethnic microdifferentiation.

Determinants of statistical power such as sample size, disease heterogeneity, pedigree and genotyping errors, as well as the effect of the type and density of genetic markers, are a key factor in genetic studies. Studies should either have sufficient power to detect a small effect size of multiple genes or consider the use of extreme and well-defined phenotypes to detect the effect of major genes [30,31].

The term ‘metagenomics’ defines the set of mechanisms by which a community of microorganisms interacts, lives and infects animal tissues. New metagenomic approaches have disclosed crucial information about the shaping of resistance, susceptibility and loss of auto-tolerance for both infectious and ADs [49]. Indeed, new reports demonstrate that host-gene-microbial interactions are major determinants for the development of ADs. Commensal microbial communities may alter sex hormone levels and regulate AD fate in individuals with a high genetic risk load [50].

Although ADs are often diagnosed according to classification criteria, they share similar subphenotypes including signs and symptoms, non-specific autoantibodies and high levels of cytokines, which are prone to taxonomic problems [51]. ADs have a heterogeneous spectrum, the disease course differs from patient to patient and through different phases within the same patient [52]. Refining the phenotype will make the effect of certain genes in the sample more easily detectable [4]. Genetic effects may be stronger for extremes of the risk factor distribution (for example, people with onset at a very young or very old age) and for particular presentations. Therefore, restricting the sample to patients with specific characteristics, or minimizing the effect of known environmental confounders will increase the chances for genetic research to be successful.
Disease heterogeneity should be minimized by considering subphenotypes or otherwise by adjusting for known sources of heterogeneity as a covariate. Meta-analysis and data pooling between different research groups can provide a sizeable study, but both approaches require a high level of vigilance about locus and disease heterogeneity when data come from different populations. Spurious associations are often due to population stratification, cryptic relatedness and differential bias [53].

GWAS have a high power to detect common variants of high or moderate effect. For weaker effects (for example, relative risk <1.2), the power is greatly reduced, particularly for recessive loci if the frequency of the variant is common (that is, rare variants) [54]. Larger size cohorts can be used to study common diseases, but meta-analyses and data pooling are required to attain a study size of sufficient magnitude for many other diseases [53]. GWAS approaches are known to be poor in detecting effects from rare alleles (that is, frequency <5%), but novel methods and technology, such as exome and whole genome sequencing will fill this gap to further support the genetic commonality of autoimmune traits [55]. However, once a polymorphism has been found to be associated with a trait, it’s functional relevance must be examined and its biological effect on such a trait understood (that is, functional genomics).

Recent advances in multiplexed assay technology are taking us closer toward the identification of ‘actionable markers,’ capable of informing and providing biological metrics of use in clinical practice. Not only will they help gain insights into the onset, remission and exacerbation of a pathology, they will improve and enhance treatment, diagnosis and classification [56].

Personalized medicine is committed to survey, monitor and diagnose risks to provide patients with a specific treatment, taking into account their particular genetic profile and molecular phenotype. Thus evaluation, comparison, correlation, cross-matching and interaction of the nascent ‘omic’ information would not only aid in the prediction, diagnosis and treatment at the individual level but also provide insights into the physiopathological mechanisms of disease onset and progression. For such purposes, an integrative personal ‘omics’ profile such as the one suggested by Chen et al. [60] will be useful to examine as many biological components as possible. Although these components might change during healthy and diseased states, this information combined with genomic information will be useful to estimate disease risk and gain new insights into diseased states [60]. Disease would be considered as a hierarchical biological system composed of molecular and functional cell, tissue and organ interactive networks. Any aberration in one or more networks will not only have local effects but also systemic effects because no cell, tissue or organ is isolated or independent.

Last but not least, safeguarding for all study participants, whether healthy or affected, and studied family members has to be warranted. Individuals are the ‘why’ behind this overhauling of ‘omic’ and genomics approaches and research, thus their legal rights and status quo have to be defined in order to eventually be successful in applying genomic-based medicine for the benefit of human kind. ‘We shall not forget the understated idea ‘...we should not only be interested in the human genome but also in the human beings that carry it’ [61].

**What is next?**

Genomics normally implies the use of sequence and genome information to annotate, describe and curate functionality and structure, in order to decipher and disentangle functionality and organization. New ‘omics’ approaches are starting to take this further by correlating and matching layers of genome-wide information to explain and to explore mechanisms of interaction between genetic and environmental factors. Significant advances in human ‘omics’ are giving rise to new possibilities in medicine, such as clinical bioinformatics [57] and translational bioinformatics [58]. All these options lead to one common premise: ways of mining meaningful information from the vast amount of ‘omics’ data being generated. In this sense, application of comprehensive molecular information to clinical settings is been referred to as ‘genomic medicine’ [59] with the ultimate goal to nurture, improve and frame personalized medicine. A genomic medicine approach will always require participation at a multidisciplinary research expertise level.

**Abbreviations**

ADs: Autoimmune diseases; GWAS: Genome-wide association study.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

JMA designed the review. JC, MAB and JMA jointly wrote the manuscript. All authors read and approved the final version of the manuscript.

**Acknowledgements**

This work was supported by Universidad del Rosario and Colciencias (122254531722), Bogota, Colombia.

**Author details**

1. Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 #63-C-69, Bogota, Colombia. 2. Doctoral Program in Biomedical Sciences, Universidad del Rosario, Bogotá, Colombia. 3. Center for Personalized Medicine, South Texas Health Care System, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 4. Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 5. Genome Biology Department, John Curtin School of Medical Research, ANU College of Medicine, Biology and Environment, The Australian National University, Canberra, Australia.

Received: 8 April 2013 Accepted: 12 August 2013 Published: 4 September 2013
References

1. Green ED, Guyer MS: Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204–213.

2. Hennekam RC, Biesecker LG: Next-generation sequencing demands next-generation phenotyping. Hum Mutat 2012, 33:884–886.

3. Chan G, Ginsburg GS: Personalized medicine: progress and promise. Ann Rev Genomics Hum Genet 2011, 12:217–234.

4. Anaya JM: Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 2012, 11:781–784.

5. Arcos-Burgos M, Velez JJ, Solomon BD, Muenke M: A common genetic network underlies use disorders and disruptive or externalizing disorders. Hum Genet 2012, 131:917–929.

6. Salovieff N, Costaplas C, Lee PH, Purcell SM, Smoller JW: Pleiotropy in complex traits: challenges and strategies. Nature Rev Genet 2013, 14:483–495.

7. Cardenas-Roldan J, Rojas-Villarraga A, Anaya JM: How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med 2013, 11:73.

8. Tobon GJ, Pers JO, Canas CA, Rojas-Villarraga A, Youinou P, Anaya JM: Are autoimmune diseases predictable? Autoimmun Rev 2012, 11:239–266.

9. Anaya JM, Gomez L, Cardiblanco J: Is there a common genetic basis for autoimmune diseases? Clin Immunol 2006, 13:185–195.

10. Somers EC, Thomas SL, Smeeth L, Hall AJ: Autoimmune diseases co-occurring within and individuals: a systematic review. Epidemiology 2006, 17:202–217.

11. Anaya JM, Corena R, Cardiblanco J, Rojas-Villarraga A, Shoenfeld Y: The kaleidoscope of immunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol 2007, 3:623–635.

12. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM: Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmun Dis 2012, 2012:2534319.

13. Richard-Miceli C, Criswell LA: Emerging patterns of genetic overlap across autoimmune disorders. Genome Med 2012, 4:6.

14. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Riddick WE, McFarland HF, Trent JM: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A 1998, 95:9979–9984.

15. Goris A, Liston A: The immunogenetic architecture of autoimmune disease. Cold Spring Harb Perspect Biol 2012, 4:a007260.

16. Bogdanos DP, Smyk DS, Rappoouilu EJ, Mytilineous MG, Heneghan MA, Selmi C, Gerthwien ME: Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012, 38:156–169.

17. Czyz W, Morahan JM, Ebers GC, Ramagopalan SV: Genetic, environmental and stochastic factors in monogenic vs. polygenic disease: a focus on epigenetic differences. BMC Med 2012, 10:93.

18. Selmi C, Lu Q, Humber MC: Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012, 39:253–259.

19. Biswas BB, Reveille JD, Beatty TH, Meyers DA, Arnett FC: Evidence that autoimmunity is a Mendelian dominant trait. Am J Hum Genet 1986, 38:584–602.

20. Arcos-Burgos M, Parodi E, Salgar M, Bedoya E, Jaramillo D, Fernandez-Calleja G, Uribe A, Fonseca I, Palacio G, Anaya JM: Origins of autoimmune diseases no longer exist. Autoimmun Rev 2012, 11:267–275.

21. Miller FW, Allison LD, Costenbader KH, Kamen DL, Langford CF, Vannberg FO, Knight JC: High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 2018, 14:e1007628.

22. Shendure J, Gerstein M: The expanding scope of DNA sequencing. Nature Biotechnol 2012, 30:1084–1094.

23. Lij Beermeister M: Genetical: combining genetic and expression analysis. Methods Mol Genet 2005, 17:49–52.

24. Lij Beermeister M, Veldhuis J: High-resolution analysis of expression-ETTs provides insight into human gene regulation. PLoS Genet 2006, 2:e1000214.

25. Behrens T, Shendure J, Lieberman E, Lander ES, de Bakker PIW, Seldin MF, Fodor SP, Eichler E, Green EM: Genome-wide association studies: an analysis of Genome-wide Association Study Consortia. Eur J Hum Genet 2012, 20:131–142.

26. Leytan E: Genome to phenotype lessons from model organisms for human genetics. Nature Rev Genet 2013, 14:168–178.

27. Mori M, Yamada R, Kobayashi K, Kawai R, Yamamoto K: Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 2005, 50:264–266.

28. Slosa S: Observations on recent studies showing increased co-occurrence of autoimmune diseases. J Autoimmun 2002, 18:251–257.

29. Quintero OL, Amador-Patatoro MO, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM: Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012, 38:119–119.

30. Hirschhorn JN, Gajdos ZK: Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Ann Rev Med 2011, 62:11–24.

31. Lessard CJ, Ice JA, Adrianto I, Wiley GB, Kelly JA, Gaffney PM, Montgomery CG, Moser KL: The genomics of autoimmune disease in the era of genome-wide association studies and beyond. Autoimmun Rev 2012, 11:267–275.

32. Pearson TA, Manolios TA: How to interpret a genome-wide association study. JAMA 2008, 299:1335–1344.

33. Barsh GS, Copenhaver GP, Gibson G, Williams SM: Guidelines for genome-wide association studies. PLoS Genet 2012, 8:e1002812.

34. Austin MA, Hair MS, Fullerton SM: Research guidelines in the era of large-scale collaborations: an analysis of Genome-wide Association Study Consortium. Am J Epidemiol 2012, 175:1308–1315.

35. Cotsapas C, Haffner DA: Immune-mediated disease genetics: the shared basis of pathogenesis. Trends Immunol 2013, 34:22–26.

36. Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, Abecasis GR, Barrett JC, Bebirian T, Cho J, De Jager PL, Elder GT, Graham RR, Gregory P, Rask-Velhelm C, Siminovitch KA, van Heel DA, Wijmenga C, Worthington J, Todd JA, Haffner DA, Rich SS, Daly MJ, FOCIS Network of Consortia: Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet 2013, 9:e1003225.

37. Lee S, Kwon MS, Park T: Network graph analysis of gene-gene interactions in genome-wide association study data. Genomics Inform 2012, 10:56–262.

38. Shendure J, Lieberman Aiden E: The expanding scope of DNA sequencing. Nature Biotechnol 2012, 30:1084–1094.
52. Castiblanco J, Anaya JM: The nature and nurture of common autoimmunity. Ann N Y Acad Sci 2007, 1109:1–8.
53. Nsengimana J, Bishop DT: Design considerations for genetic linkage and association studies. Methods Mol Biol 2012, 850:237–262.
54. Hunt KA, Mistry V, Bockett NA, Ahmad T, Ban M, Barker JN, Barrett JC, Blackburn H, Brand O, Burren O, Capon F, Compton A, Gough SC, Jostins L, Kong Y, Lee JC, Lek M, MacArthur DG, Mansfield JC, Mathew CG, Mein CA, Mirza M, Nutland S, Onengut-Gumuscu S, Papouli E, Parkes M, Rich SS, Sawyer S, Satsangi J, Simmonds MJ, et al: Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature 2013, 498:232–235.
55. Voight BF, Cotsapas C: Human genetics offers an emerging picture of common pathways and mechanisms in autoimmunity. Curr Opin Immunol 2012, 24:552–557.
56. Maeker HT, Lindstrom TM, Robinson WH, Utz PJ, Hale M, Boyd SD, Shen-Orr SS, Fathman CG: New tools for classification and monitoring of autoimmune diseases. Nature Rev Rheumatol 2012, 8:317–328.
57. Knaup P, Ammenwerth E, Brandner R, Brigl B, Fischer G, Garde S, Lang E, Pilgram R, Rudensch F, Singer R, Wolff AC, Haux R, Kulkowski C: Towards clinical bioinformatics: advancing genomic medicine with informatics methods and tools. Methods Inf Med 2004, 43:302–307.
58. Kann MG: Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Brief Bioinform 2010, 11:96–110.
59. Feero WG, Guttmacher AE, Collins FS: Genomic medicine—an updated primer. N Engl J Med 2010, 362:2001–2011.
60. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Miriami E, Karczewski KJ, Harirhan M, Dewey FE, Cheng Y, Clark MU, Im H, Habegger L, Balasubramanian S, O’Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroix M, Borel T, Bettinger K, Boyle A, Kasowski M, Grubert F, Seiki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, et al: Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293–1307.
61. Bernal JE: Human diversity in Colombia. Science 1995, 267:774.